JP2004533235A - 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法 - Google Patents

治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法 Download PDF

Info

Publication number
JP2004533235A
JP2004533235A JP2002582180A JP2002582180A JP2004533235A JP 2004533235 A JP2004533235 A JP 2004533235A JP 2002582180 A JP2002582180 A JP 2002582180A JP 2002582180 A JP2002582180 A JP 2002582180A JP 2004533235 A JP2004533235 A JP 2004533235A
Authority
JP
Japan
Prior art keywords
polypeptide
novx
nucleic acid
protein
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002582180A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004533235A5 (enExample
Inventor
リ・リ
バレリー・ガーラッチ
シャオホン・リュー
チャールズ・イー・ミラー
キンバリー・エイ・スピテック
ブライアン・ディ・ザーフーゼン
キャロル・イー・エイ・ピーナ
スレシュ・ジー・シェノイ
ジョン・ハイホン
グレンダ・スミスソン
ステイシー・ジェイ・キャスマン
フェレンツ・エル・ボルドグ
エドワード・ゼット・ボス
コリーヌ・ア・ヴェルネ
ジョン・アール・マクドゥゴール
ルカ・ラステッリ
デイビッド・ダブリュー・アンダーソン
メイ・ジョン
ピーター・エス・メゼス
カタルジナ・ファータック
メーラ・パトゥラジャン
キャサリン・イー・バージェス
ウリエル・エム・マルヤンカル
リチャード・エイ・シムケッツ
レイモンド・ジェイ・トーピアー・ジュニア
シュロミット・エディンガー
アン・マザー
Original Assignee
キュラジェン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キュラジェン コーポレイション filed Critical キュラジェン コーポレイション
Publication of JP2004533235A publication Critical patent/JP2004533235A/ja
Publication of JP2004533235A5 publication Critical patent/JP2004533235A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2002582180A 2001-04-03 2002-04-03 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法 Pending JP2004533235A (ja)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
US28113601P 2001-04-03 2001-04-03
US28190601P 2001-04-05 2001-04-05
US28186301P 2001-04-05 2001-04-05
US28293401P 2001-04-10 2001-04-10
US28371001P 2001-04-13 2001-04-13
US28367801P 2001-04-13 2001-04-13
US28365701P 2001-04-13 2001-04-13
US28368701P 2001-04-13 2001-04-13
US28423401P 2001-04-17 2001-04-17
US28532501P 2001-04-19 2001-04-19
US28560901P 2001-04-20 2001-04-20
US28589001P 2001-04-23 2001-04-23
US28574801P 2001-04-23 2001-04-23
US28606801P 2001-04-24 2001-04-24
US28721301P 2001-04-27 2001-04-27
US28850901P 2001-05-03 2001-05-03
US29449501P 2001-05-30 2001-05-30
US29480101P 2001-05-31 2001-05-31
US30921601P 2001-07-31 2001-07-31
US32477501P 2001-09-25 2001-09-25
US33390001P 2001-11-28 2001-11-28
US10/115,479 US20040006205A1 (en) 2001-04-03 2002-04-02 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
PCT/US2002/010713 WO2002083841A2 (en) 2001-04-03 2002-04-03 Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Publications (2)

Publication Number Publication Date
JP2004533235A true JP2004533235A (ja) 2004-11-04
JP2004533235A5 JP2004533235A5 (enExample) 2006-01-05

Family

ID=29716460

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002582180A Pending JP2004533235A (ja) 2001-04-03 2002-04-03 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法

Country Status (5)

Country Link
US (1) US20040006205A1 (enExample)
EP (1) EP1399537A4 (enExample)
JP (1) JP2004533235A (enExample)
CA (1) CA2442729A1 (enExample)
WO (1) WO2002083841A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213676A1 (en) * 2002-03-04 2003-09-22 Bristol-Myers Squibb Company Novel nucleic acid molecules and polypeptides encoding baboon tafi
WO2004054156A2 (en) * 2002-12-06 2004-06-24 Fast Country, Inc. Systems and methods for providing interactive guest resources
MXPA05005923A (es) * 2002-12-06 2005-09-21 Millennium Pharm Inc Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
GB0523373D0 (en) * 2005-11-16 2005-12-28 Ares Trading Sa Nidogen/snep-like molecule
PL226806B1 (pl) * 2010-12-06 2017-09-29 Inst Medycyny Doświadczalnej I Klinicznej Im Mirosława Mossakowskiego Pan Preparaty peptydowe oraz peptydy odziałaniu przeciwnowotworowym
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN108753926B (zh) * 2018-06-05 2022-03-01 安徽省农业科学院畜牧兽医研究所 一种猪背部脂肪厚度的分子标记方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ206534A (en) * 1982-12-13 1988-05-30 Florey Howard Inst Molecular cloning and characterisation of gene sequence coding for human relaxin
AU612594B2 (en) * 1986-09-12 1991-07-18 Genentech Inc. Human prorelaxin
US5710014A (en) * 1988-02-11 1998-01-20 The United States Of America As Represented By The Department Of Health And Human Services Cloned cDNA for human procathepsin l.
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
US5478807A (en) * 1991-08-19 1995-12-26 Genentech, Inc. Use of relaxin in the treatment of bradycardia
US5166191A (en) * 1991-08-19 1992-11-24 Genentech, Inc. Use of relaxin in cardiovascular therapy
CA2165781C (en) * 1993-06-21 2007-02-13 Tim Breece Process for producing relaxin
US5871723A (en) * 1995-06-06 1999-02-16 The Regent Of The University Of Michigan CXC chemokines as regulators of angiogenesis
WO1996041167A1 (en) * 1995-06-07 1996-12-19 Connective Therapeutics, Inc. Relaxin diagnostic assays and kits, and methods and uses thereof
US6083693A (en) * 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
US6046028A (en) * 1996-10-15 2000-04-04 Zymogenetics, Inc. Polynucleotides encoding insulin homolog zins3
KR100685105B1 (ko) * 1997-12-19 2007-02-22 와이어쓰 연골의 퇴행성 질환용 트랜스제닉 동물 모델
WO1999040929A1 (en) * 1998-02-12 1999-08-19 The General Hospital Corporation Methods to potentiate cancer therapies
US6107549A (en) * 1998-03-10 2000-08-22 Monsanto Company Genetically engineered plant resistance to thiazopyr and other pyridine herbicides
EP1826569A1 (en) * 1999-05-17 2007-08-29 Cytyc Corporation Identifying material from a breast duct
WO2001060860A2 (en) * 2000-02-17 2001-08-23 Millennium Predictive Medicine, Inc. Genes differentially expressed in human prostate cancer and their use
NZ525389A (en) * 2000-10-04 2009-04-30 Molecular Medicine Res Inst Methods of modulating apoptosis by administration of relaxin agonists or antagonists
PA8539301A1 (es) * 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz

Also Published As

Publication number Publication date
CA2442729A1 (en) 2002-10-24
US20040006205A1 (en) 2004-01-08
EP1399537A2 (en) 2004-03-24
WO2002083841A2 (en) 2002-10-24
EP1399537A4 (en) 2006-09-06
WO2002083841A3 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
WO2004015060A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002079398A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002081625A2 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
EP1401858A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2003078572A2 (en) Therapeutic polypeptides, nucleic acids encoding same and methods of use
EP1432726A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP2004533235A (ja) 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法
JP2005519629A (ja) 治療ポリペプチドとコード化核酸と使用方法
JP2006516082A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2006501813A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法
JP2005506054A (ja) 抗原性治療的ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
WO2002090500A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2006509491A (ja) 新規蛋白およびそれらをコードする核酸
WO2002081629A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005506833A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコード化する核酸、および使用方法
JP2005507236A (ja) 抗原性ポリペプチドに結合する新規抗体、抗原をコードする核酸、および使用方法
US20060211031A1 (en) Novel proteins and nucleic acids encoding same
WO2003052061A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2003085096A2 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US20060210559A1 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
JP2005504514A (ja) 治療用ポリペプチド、それをコードする核酸、および使用方法
US20060111561A1 (en) Novel proteins and nucleic acids encoded thereby
JP2005505247A (ja) 治療用ポリペプチド、該ポリペプチドをコードする核酸、および使用方法
WO2002098900A2 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
JP2005518200A (ja) 治療ポリペプチド、それをコードする核酸、および使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050331

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20070222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070807

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071015

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080306